Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,994 EUR | +2,63% | -2,76% | +34,92% |
07/05 | Koersdoel AstraZeneca verhoogd; Antofagasta verlaagd | AN |
03/05 | AIB GROUP : Sterkere inkomstengroei en gunstige risicokosten |
Omzet 2024 * | 4,56 mld. 4,96 mld. | Omzet 2025 * | 4,34 mld. 4,72 mld. | Marktkapitalisatie | 12,07 mld. 13,13 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 1,76 mld. 1,92 mld. | Nettowinst (verlies) 2025 * | 1,56 mld. 1,7 mld. | EV/omzet 2024 * | 2,65 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,78 x |
K/w-verhouding 2024 * |
6,95
x | K/w-verhouding 2025 * |
7,23
x | Werknemers | 10.551 |
Dividendrendement 2024 * |
6,03% | Dividendrendement 2025 * |
6,39% | Vrij verhandelbaar | 67,6% |
Recentste transcriptie over AIB Group plc
1 dag | +2,63% | ||
1 week | -2,76% | ||
Lopende maand | +2,67% | ||
1 maand | +3,70% | ||
3 maanden | +25,38% | ||
6 maanden | +22,58% | ||
Lopend jaar | +34,92% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 01-01-16 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 01-09-13 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Fergal O’Dwyer
BRD | Director/Board Member | 64 | 22-01-21 |
James Pettigrew
CHM | Chairman | 65 | 28-10-21 |
Brendan McDonagh
BRD | Director/Board Member | 66 | 27-10-16 |
Datum | Koers | Variatie |
---|---|---|
15-05-24 | 4,93 | +1,32% |
14-05-24 | 4,866 | -3,64% |
13-05-24 | 5,05 | +3,02% |
10-05-24 | 4,902 | -2,74% |
09-05-24 | 5,04 | -0,59% |
uitgestelde koers Deutsche Boerse AG, 15 mei 2024 om 08:32 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,72% | 579 mld. | |
+15,35% | 301 mld. | |
+17,02% | 250 mld. | |
+25,91% | 216 mld. | |
+19,57% | 180 mld. | |
+23,83% | 168 mld. | |
+10,42% | 165 mld. | |
+6,78% | 147 mld. | |
-15,84% | 133 mld. |